伦韦单抗(INN:Lenvervimab;[1]开发代号:GC1102)是一种单克隆抗体,被研究来针对乙型肝炎。[2]该药物由韩国制药公司绿十字集团开发。截至2018年,伦韦单抗正在进行II/III期试验。
参考资料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118 (PDF). WHO Drug Information. 2017, 31 (4) [2023-10-06]. (原始内容存档 (PDF)于2020-08-15).
- ^ Jeong GU, Ahn BY, Jung J, Kim H, Kim TH, Kim W, Lee A, Lee K, Kim JH. A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants. PLOS ONE. 2020, 15 (8): e0236704. Bibcode:2020PLoSO..1536704J. PMC 7425877 . PMID 32790777. doi:10.1371/journal.pone.0236704 .